Cellectar Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 27, 2018, reports on a material definitive agreement entered into by Cellectar Biosciences, Inc. (the "Company"). The filing details an underwritten public offering that closed on July 31, 2018. The Company is a Delaware corporation headquartered in Madison, Wisconsin.
Key Financial Metrics and Transaction Details
- Net Proceeds: Approximately $15 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Securities Issued:
- 815,000 shares of Common Stock.
- 1,114 shares of Series C Convertible Preferred Stock (convertible into 2,785,000 shares of Common Stock).
- Series E Warrants to purchase 3,600,000 shares of Common Stock.
- Offering Prices:
- Common Stock + Warrant: $4.00 per unit.
- Series C Preferred Stock + Warrant: $10,000 per unit (convertible into 2,500 shares of Common Stock).
- Over-Allotment Option: A 45-day option to purchase up to 540,000 additional shares of Common Stock and corresponding Warrants was granted to the underwriters and was exercised in full on July 30, 2018.
- Post-Offering Capitalization: As of July 31, 2018, the Company had 3,402,825 shares of Common Stock outstanding (including shares from Series C conversion) and 1,015 shares of Series C Preferred Stock outstanding.
Material Changes and Corporate Actions
The primary material change is the significant increase in equity capitalization resulting from the public offering. In connection with the closing, the Company filed a Certificate of Designation for the Series C Preferred Stock with the Delaware Secretary of State. This filing established specific voting rights and protective provisions for Series C holders, including veto rights over amendments adversely affecting their rights or increasing authorized Series C shares.
Guidance, Outlook, and Restrictions
The filing does not provide specific financial guidance or operational outlook beyond the completion of the capital raise. However, it notes a standard lock-up provision: the Company and its directors and officers agreed not to offer, issue, or sell any shares of common stock or convertible securities for 90 days following July 31, 2018, without the prior written consent of the underwriters.
Key Facts for Investor Verification
- Verify the final net proceeds of approximately $15 million against the actual closing statement.
- Confirm the full exercise of the 540,000 share over-allotment option on July 30, 2018.
- Review the specific terms of the Series C Preferred Stock Certificate of Designation regarding voting rights and conversion mechanics.
- Monitor the 90-day lock-up period expiration date (approximately October 30, 2018) for potential dilution risks.
- Check the total outstanding share count of 3,402,825 Common Stock shares as of July 31, 2018.